E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 7.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10061992 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
• To evaluate the intra-subject variability (in vivo reproducibility) of thromboelastographic parameters as measured by ROTEM® and by TEG® prior to and at 15, 60, 120 and 240 minutes following two administrations of the same dose of activated recombinant human FVII (rFVIIa) in haemophilia patients in a non bleeding state |
|
E.2.2 | Secondary objectives of the trial |
• To evaluate whether there is a correlation between different doses of rFVIIa and the ROTEM® and TEG® parameters • To evaluate whether there is a correlation between thromboelastographic parameters as determined by ROTEM® and by TEG® • To compare the in vivo reproducibility of thromboelastographic parameters as determined by ROTEM® and by TEG® • To evaluate the inter-subject variability of thromboelastographic parameters as measured by ROTEM® and by TEG® • To evaluate whether there is a correlation between the response of in vivo and ex vivo supplementation of rFVIIa • To evaluate whether there is a correlation between the in vivo ROTEM® or TEG® parameters and the following parameters FVIIa:C, FX:C, Fibrinogen, Number of platelets and total platelet volume, PT and aPTT • To evaluate the safety of rFVIIa administration |
|
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
• Informed consent obtained before any trial-related activities. (Trial-related activities are any procedure that would not have been performed during normal management of the patient.) • Confirmed diagnosis of congenital haemophilia A or B with a FVIII:C or FIX:C one stage activity, respectively, at less than 5% of normal (based on medical records) +/- inhibitors (a positive inhibitor status defined as >0.6 Bethesda units) • Male subjects, 16 years of age or more • Non-bleeding state (i.e. no clinical manifestation of active bleed) at the time of administration of trial product
|
|
E.4 | Principal exclusion criteria |
• Known or suspected allergy to trial product or any of its components or to related products • Previous participation in this trial defined as randomisation of the patient • Known clinically relevant coagulation disorders or insufficiencies other than congenital haemophilia A or B • Platelet count < 50,000 platelets/μL • Received any haemostatic treatment (e.g. Feiba) within the last 7 days prior to administration of trial product, except for rFVIIa • Received rFVIIa within the last 48 hours prior to administration of trial product • Participation in any other trial involving investigational products within the last 30 days prior to administration of trial product • Received immunosuppressive-immunomodulatory drugs within the last 30 days prior to administration of trial product • Advanced atherosclerotic disease, incl. any history of thrombotic disorder (myocardial infarction, deep vein thrombosis, pulmonary embolism, stroke or peripheral arterial thrombosis) • Septicaemia, e.g. febrile illness within 5 days prior to trial product administration • Renal insufficiency defined as current dialysis therapy or creatinine levels above normal range (according to local laboratory range) • Hepatic disease Patients with significant hepatic enzyme elevation (ALAT x 2 upper reference limit and/or PT<70%) Known current hepatic dysfunction or severe hepatic disease during the last 12 months. • Any disease or condition which, according to the Investigator´s judgement, could imply a potential hazard to the patient, interfere with the trial participation or trial outcome • Mental incapacity, unwillingness or language barriers precluding adequate understanding or co-operation |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary endpoints • TEG® parameters (R time, K time, α, MA and LY30) prior to and at 15, 60, 120, 240 minutes after dosing of rFVIIa • ROTEM® parameters (CT, CFT, α, MCT and LI60) prior to and at 15, 60, 120, 240 minutes after dosing of rFVIIa
Secondary endpoints • TEG® parameters (R time, K time, α, MA and LY30) obtained from blood samples spiked ex-vivo with rFVIIa (corresponding to 45, 90 and 180 μg/kg) • ROTEM® parameters (CT, CFT, α, MCT and LI60) obtained from blood samples spiked ex-vivo with rFVIIa (corresponding to 45, 90 and 180 μg/kg) • FVIIa:C, FX:C, fibrinogen, number of platelets and total platelet volume, PT and aPTT prior to and at 15, 60, 120, 240 minutes after dosing of rFVIIa • Serious adverse events regardless of causality and non-serious adverse events judged by the Investigator to be related to trial product administration
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Information not present in EudraCT |
E.6.2 | Prophylaxis | Information not present in EudraCT |
E.6.3 | Therapy | Information not present in EudraCT |
E.6.4 | Safety | Information not present in EudraCT |
E.6.5 | Efficacy | Information not present in EudraCT |
E.6.6 | Pharmacokinetic | Information not present in EudraCT |
E.6.7 | Pharmacodynamic | Information not present in EudraCT |
E.6.8 | Bioequivalence | Information not present in EudraCT |
E.6.9 | Dose response | Information not present in EudraCT |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | Information not present in EudraCT |
E.6.12 | Pharmacoeconomic | Information not present in EudraCT |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Investigation of TEG® or ROTEM® as a general dose predictive marker(s) in haemophilia |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | Yes |
E.7.1.3.1 | Other trial type description |
Intra-subject variability of ROTEM and TEG parameters |
|
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
14 days after last patient’s last visit: A telephone interview taking place two weeks after the dosing visits ensures complete adverse event information |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 6 |